Ka Yu Tse
YOU?
Author Swipe
View article: Oligoclonal tumor-specific CD8 T-cell revival and IRE1α/XBP1-GDF15-mediated immunosuppressive niches determine neoadjuvant chemoimmunotherapy efficacy in cervical cancer
Oligoclonal tumor-specific CD8 T-cell revival and IRE1α/XBP1-GDF15-mediated immunosuppressive niches determine neoadjuvant chemoimmunotherapy efficacy in cervical cancer Open
Background Neoadjuvant chemoimmunotherapy (NACI) shows promise for locally advanced cervical cancer (LACC), but drug-tolerant persister (DTP) cells and immunosuppressive microenvironmental adaptations limit clinical efficacy. The underlyin…
View article: Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives
Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives Open
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by leveraging the immune system's capacity to fight gynecologic cancer. This review summarizes the current status and future perspectives of ICIs in the treatment of cer…
View article: CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study
CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study Open
View article: The perioperative complications of vertebral body tethering
The perioperative complications of vertebral body tethering Open
Aims There is little information in the orthopaedic literature about the rate of perioperative complications of vertebral body tethering (VBT), in the surgical management of patients with adolescent idiopathic scoliosis. The aim of this st…
View article: Multi-Omics Analysis Reveals the transforming growth factor-β Signaling-Driven Multicellular Interactions with Prognostic Relevance in Cervical Cancer Progression
Multi-Omics Analysis Reveals the transforming growth factor-β Signaling-Driven Multicellular Interactions with Prognostic Relevance in Cervical Cancer Progression Open
While cervical cancer (CC) prognosis depends on tumor staging, the spatiotemporal evolution of tumor microenvironment (TME) heterogeneity during metastatic progression remains poorly characterized at single-cell resolution. We employed an …
View article: The intratumoral microbiota heterogenicity is related to the prognosis and tumorigenesis of cervical cancer
The intratumoral microbiota heterogenicity is related to the prognosis and tumorigenesis of cervical cancer Open
Background The intratumoral microbe-host interaction plays crucial role in the development of cancer. The microbiome can influence cancer development by modulating inflammation, immune responses and metabolic pathways. Therefore, we aim to…
View article: Return to intended oncological therapy following advanced ovarian cancer surgery: a narrative review
Return to intended oncological therapy following advanced ovarian cancer surgery: a narrative review Open
Summary Introduction Patients with advanced ovarian cancer often require radical cytoreductive surgery and chemotherapy, with or without targeted therapy. Return to intended oncological therapy after surgery is a crucial metric, as delay c…
View article: Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80) Open
ClinicalTrials.gov Identifier: NCT06023862.
View article: <scp>PAX1</scp>/<scp>SOX1 DNA</scp> Methylation Versus Cytology and <scp>HPV16</scp>/18 Genotyping for the Triage of High‐Risk <scp>HPV</scp>‐Positive Women in Cervical Cancer Screening: Retrospective Analysis of Archival Samples
<span>PAX1</span>/<span>SOX1 DNA</span> Methylation Versus Cytology and <span>HPV16</span>/18 Genotyping for the Triage of High‐Risk <span>HPV</span>‐Positive Women in Cervical Cancer Screening: Retrospective Analysis of Archival Samples Open
Objective To compare the performance of cytology, HPV16/18 genotyping and PAX1/SOX1 methylation for the triage of high‐risk HPV‐positive cervical samples. Design Retrospective analyses of archival samples collected from a large‐scale prosp…
View article: Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S3. Autopsy findings on a representative mouse treated with 7.5 mg/kg CFI-400945 (hematoxylin and eosin staining).
View article: Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S2. DNA content and centrosome number quantification in myogenic sarcoma cell lines after CFI-400945 treatment.
View article: Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S2. DNA content and centrosome number quantification in myogenic sarcoma cell lines after CFI-400945 treatment.
View article: Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S5. Oncoplot of key genes responsible for DNA repair among sarcoma cell lines.
View article: Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Data S1. Small variants, copy number alterations, structural variants, and fusion transcripts of DNA repair genes.
View article: Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S1. Sanger sequencing of SK-UT-1 and SKN BRAC2-KO.
View article: Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Purpose:Uterine leiomyosarcoma (LMS) is an aggressive sarcoma and a subset of which exhibits DNA repair defects. Polo-like kinase 4 (PLK4) precisely modulates mitosis, and its inhibition causes chromosome missegregation and increased DNA d…
View article: Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Data S1. Small variants, copy number alterations, structural variants, and fusion transcripts of DNA repair genes.
View article: Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S6. Genomic alterations involving key genes responsible for DNA repair in uterine leiomyosarcoma.
View article: Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S5. Oncoplot of key genes responsible for DNA repair among sarcoma cell lines.
View article: Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Table S1. Clinicopathologic features of 25 uterine leiomyosarcoma.
View article: Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S3. Autopsy findings on a representative mouse treated with 7.5 mg/kg CFI-400945 (hematoxylin and eosin staining).
View article: Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S1. Sanger sequencing of SK-UT-1 and SKN BRAC2-KO.
View article: Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S6. Genomic alterations involving key genes responsible for DNA repair in uterine leiomyosarcoma.
View article: Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Purpose:Uterine leiomyosarcoma (LMS) is an aggressive sarcoma and a subset of which exhibits DNA repair defects. Polo-like kinase 4 (PLK4) precisely modulates mitosis, and its inhibition causes chromosome missegregation and increased DNA d…
View article: Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Table S1. Clinicopathologic features of 25 uterine leiomyosarcoma.
View article: Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S4. Autopsy findings on two mice from two different 5 mg/kg CFI-400945 treatment groups that were withdrawn from the experiments (hematoxylin and eosin staining).
View article: Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S4. Autopsy findings on two mice from two different 5 mg/kg CFI-400945 treatment groups that were withdrawn from the experiments (hematoxylin and eosin staining).
View article: Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer Open
PURPOSE Patients with advanced endometrial cancer (EC) who progress on or after platinum-based therapy and immunotherapy have poor prognosis. We report efficacy and safety of sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2…
View article: Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Purpose: Uterine leiomyosarcoma (LMS) is an aggressive sarcoma and a subset of which exhibits DNA repair defects. Polo-like kinase 4 (PLK4) precisely modulates mitosis, and its inhibition causes chromosome missegregation and increased DNA …
View article: Comparison of the multiples of the median of serum anti‐müllerian hormone and pregnancy outcomes in patients with gestational trophoblastic disease: A case–control study
Comparison of the multiples of the median of serum anti‐müllerian hormone and pregnancy outcomes in patients with gestational trophoblastic disease: A case–control study Open
Introduction Chemotherapy is crucial in treating gestational trophoblastic neoplasia (GTN), but its impact on gonadotoxicity is unclear. Materials and Methods This case–control study included 57 GTN patients and 19 age‐matched patients wit…